目的 探討司美格魯肽聯(lián)合羅格列酮治療2型糖尿病的臨床療效。方法 選取2021年5月—2023年7月黃山首康醫(yī)院內(nèi)分泌科收治的80例2型糖尿病患者，依據(jù)用藥情況將所有患者分為對照組和治療組，每組各40例。對照組患者口服馬來酸羅格列酮片，4 mg/次，1次/d。治療組患者在對照組的治療基礎(chǔ)上皮下注射司美格魯肽注射液，0.25 mg/次，1次/周；28 d后，0.5 mg/次，1次/周。兩組連續(xù)用藥12周。觀察兩組的臨床療效和癥狀好轉(zhuǎn)時間，比較兩組治療前后生活質(zhì)量評定量表（SF-36）評分、糖化血紅蛋白（HbA1c）、空腹血糖（FPG）、餐后2 h血糖（2 h PG）、空腹胰島素（FINS）、胰島素抵抗指數(shù)（HOMA-IR）、胰島β細(xì)胞指數(shù)（HOMA-β）的變化情況。結(jié)果 治療后，治療組總有效率是92.51%，顯著高于對照組的77.50%（P＜0.05）。治療后，治療組多尿、多飲、多食、體質(zhì)量減少好轉(zhuǎn)時間均顯著短于對照組（P＜0.05）。治療后，兩組SF-36評分均較同組治療前顯著提高（P＜0.05）；治療后，治療組SF-36評分高于對照組（P＜0.05）。治療后，治療組HbA1c、FPG、餐后2 h PG水平均較同組治療前顯著降低（P＜0.05）；治療后，治療組糖代謝指標(biāo)低于對照組（P＜0.05）。治療后，兩組FINS、HOMA-IR水平均顯著降低，HOMA-β顯著升高（P＜0.05）；治療后，治療組FINS、HOMA-IR指標(biāo)低于對照組，HOMA-β指標(biāo)高于對照組（P＜0.05）。結(jié)論 采用司美格魯肽和羅格列酮協(xié)同治療2型糖尿病，可較快改善患者臨床癥狀，并有效調(diào)節(jié)糖代謝相關(guān)指標(biāo)，患者生活質(zhì)量提升明顯，值得借鑒與應(yīng)用。

Objective To investigate the clinical effect of semaglutide combined with rosiglitazone in treatment of type 2 diabetes. Methods A total of 80 patients with type 2 diabetes admitted to the Department of Endocrinology of Huangshan Shoukang Hospital from May 2021 to July 2023 were selected and divided into control group and treatment group according to drug usage, with 40 patients in each group. Patients in control group were po administered with Rosiglitazone Maleate Tablets, 4 mg/time, once daily. Patients in treatment group were sc administered with Semaglutide Injection on the basis of control group, 0.25 mg/time, once weekly, and after 28 days, 0.5 mg/time, once weekly. Both groups were treated continuously for 12 weeks. The clinical efficacy and symptom improvement time of two groups were observed. The changes of life quality, rating Scale (SF-36), glycated hemoglobin (HbA1c), fasting blood glucose (FPG), 2 h blood glucose (2 h PG), fasting insulin (FINS), insulin resistance value (HOMA-IR) and islet beta cell value (HOMA-β) before and after treatment were compared between two groups. Results After treatment, the total effective rate of treatment group was 92.51%, which was significantly higher than that of control group (77.50%, P < 0.05). After treatment, the improvement time of polyuria, polydipsia, polyfood, and body mass reduction in treatment group was significantly shorter than that in control group (P < 0.05). After treatment, SF-36 scores in both groups were significantly higher than those before treatment (P < 0.05). After treatment, the SF-36 score in the treatment group was higher than that in control group (P < 0.05). After treatment, the levels of HbA1c, FPG, and 2 h PG in treatment group were significantly decreased compared with those before treatment (P < 0.05). After treatment, the glucose metabolism index of treatment group was lower than that of control group (P < 0.05). After treatment, FINS and HOMA-IR levels were significantly decreased, but HOMA-β levels were significantly increased in both groups (P < 0.05). After treatment, FINS and HOMA-IR indexes in treatment group were lower than those in control group, but HOMA-β indexes were higher than those in control group (P < 0.05). Conclusion The combination of semaglutide and rosiglitazone in treatment of type 2 diabetes can quickly improve the clinical symptoms of patients, and effectively regulate the related indexes of glucose metabolism, and significantly improve the quality of life of patients, which is worth learning and application.

R977